CoChat
Sign Up
Cited by 62Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchLipid metabolism and biosynthesis

Lipidome disruption in Alzheimer’s disease brain: detection, pathological mechanisms, and therapeutic implications

Open access
He, Sijia, Xu, Ziying, Han, Xianlin·2025·Molecular Neurodegeneration
DOI 10.1186/s13024-025-00803-6PMC PMC11773937
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer’s disease (AD) is among the most devastating neurodegenerative disorders with limited treatment options. Emerging evidence points to the involvement of lipid dysregulation in the development of AD. Nevertheless, the precise lipidomic landscape and the mechanistic roles of lipids in disease pathology remain poorly understood. This review aims to highlight the significance of lipidomics and lipid-targeting approaches in the diagnosis and treatment of AD. We summarized the connection between lipid dysregulation in the human brain and AD at both genetic and lipid species levels. We briefly introduced lipidomics technologies and discussed potential challenges and areas of future advancements in the lipidomics field for AD research. To elucidate the central role of lipids in converging multiple pathological aspects of AD, we reviewed the current knowledge on the interplay between lipids and major AD features, including amyloid beta, tau, and neuroinflammation. Finally, we assessed the progresses and obstacles in lipid-based therapeutics and proposed potential strategies for leveraging lipidomics in the treatment of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-025-00803-6

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 366

  1. [1]Magalingam KB, Radhakrishnan A, Ping NS, Haleagrahara N. Current concepts of neurodegenerative mechanisms in Alzheimer’s Disease. Biomed Res Int. 2018;2018:3740461. 29707568 PMC5863339 · DOI · Paper page
  2. [2]Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66(2):200–8. 19743450 PMC2812870 · DOI · Paper page
  3. [5]Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23(4):213–27. 21045163 PMC3044597 · DOI · Paper page
  4. [6]Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71(4):505–8. 24493463 PMC12908160 · DOI
  5. [8]Norat P, Soldozy S, Sokolowski JD, Gorick CM, Kumar JS, Chae Y, et al. Mitochondrial dysfunction in neurological disorders: exploring mitochondrial transplantation. NPJ Regen Med. 2020;5(1):22. 33298971 PMC7683736 · DOI
  6. [9]Allen SJ, Watson JJ, Dawbarn D. The neurotrophins and their role in Alzheimer’s disease. Curr Neuropharmacol. 2011;9(4):559–73. 22654716 PMC3263452 · DOI
  7. [10]Bretou M, Sannerud R, Escamilla-Ayala A, Leroy T, Vrancx C, Van Acker ZP, et al. Accumulation of APP C-terminal fragments causes endolysosomal dysfunction through the dysregulation of late endosome to lysosome-ER contact sites. Dev Cell. 2024;59(12):1571–92. e9. 38626765 · DOI
  8. [11]Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer’s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157(1):277–86. 10880397 PMC1850219 · DOI
  9. [12]Uddin MS, Stachowiak A, Mamun AA, Tzvetkov NT, Takeda S, Atanasov AG, et al. Autophagy and Alzheimer’s Disease: from Molecular mechanisms to therapeutic implications. Front Aging Neurosci. 2018;10:04. 29441009 PMC5797541 · DOI
  10. [13]Barmaki H, Nourazarian A, Khaki-Khatibi F. Proteostasis and neurodegeneration: a closer look at autophagy in Alzheimer’s disease. Front Aging Neurosci. 2023;15:1281338. 38020769 PMC10652403 · DOI
  11. [14]Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–6. 27582220 · DOI · Paper page
  12. [15]van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9–21. 36449413 · DOI · Paper page
  13. [16]Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512–27. 37459141 PMC10352931 · DOI · Paper page
  14. [17]Van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9(2):112–24. 18216768 PMC2642958 · DOI · Paper page
  15. [18]Wang S, Soni KG, Semache M, Casavant S, Fortier M, Pan L, et al. Lipolysis and the integrated physiology of lipid energy metabolism. Mol Genet Metab. 2008;95(3):117–26. 18762440 · DOI
  16. [19]Mutlu AS, Duffy J, Wang MC. Lipid metabolism and lipid signals in aging and longevity. Dev Cell. 2021;56(10):1394–407. 33891896 PMC8173711 · DOI
  17. [20]Shevchenko A, Simons K. Lipidomics: coming to grips with lipid diversity. Nat Rev Mol Cell Biol. 2010;11(8):593–8. 20606693 · DOI
  18. [21]Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill AH Jr., Murphy RC, et al. A comprehensive classification system for lipids. J Lipid Res. 2005;46(5):839–61. 15722563 · DOI
  19. [22]Fahy E, Subramaniam S, Murphy RC, Nishijima M, Raetz CR, Shimizu T, et al. Update of the LIPID MAPS comprehensive classification system for lipids. J Lipid Res. 2009;50(SupplSuppl):S9–14. 19098281 PMC2674711 · DOI
  20. [23]Han X, Gross RW. The foundations and development of lipidomics. J Lipid Res. 2022;63(2):100164. 34953866 PMC8953652 · DOI
  21. [24]Hamilton JA, Hillard CJ, Spector AA, Watkins PA. Brain uptake and utilization of fatty acids, lipids and lipoproteins: application to neurological disorders. J Mol Neurosci. 2007;33(1):2–11. 17901539 · DOI
  22. [25]Sastry PS. Lipids of nervous tissue: composition and metabolism. Prog Lipid Res. 1985;24(2):69–176. 3916238 · DOI
  23. [26]Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science. 2010;327(5961):46–50. 20044567 · DOI · Paper page
  24. [27]Saher G, Quintes S, Nave KA. Cholesterol: a novel regulatory role in myelin formation. Neuroscientist. 2011;17(1):79–93. 21343408 · DOI · Paper page
  25. [28]Jove M, Mota-Martorell N, Obis E, Sol J, Martin-Gari M, Ferrer I et al. Lipid adaptations against oxidative challenge in the healthy adult human brain. Antioxid (Basel) 2023;12(1). PMC9855103 36671039
  26. [29]Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015;7:52. 25954194 PMC4404917 · DOI · Paper page
  27. [30]Ronald L, Schnaar RS, Michael Tiemeyer, and Taroh Kinoshita. In: Varki A CR, Esko JD, Essentials of Glycobiology [Internet] 4th edition, Cold et al. Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022. 35536922
  28. [31]Sipione S, Monyror J, Galleguillos D, Steinberg N, Kadam V. Gangliosides in the brain: physiology, pathophysiology and therapeutic applications. Front Neurosci. 2020;14:572965. 33117120 PMC7574889 · DOI
  29. [32]Osetrova M, Tkachev A, Mair W, Guijarro Larraz P, Efimova O, Kurochkin I, et al. Lipidome atlas of the adult human brain. Nat Commun. 2024;15(1):4455. 38796479 PMC11127996 · DOI
  30. [34]Bellenguez C, Kucukali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022;54(4):412–36. 35379992 PMC9005347 · DOI · Paper page
  31. [35]de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen IE, et al. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores. Nat Commun. 2021;12(1):3417. 34099642 PMC8184987 · DOI · Paper page
  32. [37]Yin F. Lipid metabolism and Alzheimer’s disease: clinical evidence, mechanistic link and therapeutic promise. FEBS J. 2023;290(6):1420–53. 34997690 PMC9259766 · DOI · Paper page
  33. [38]Gamba P, Testa G, Gargiulo S, Staurenghi E, Poli G, Leonarduzzi G. Oxidized cholesterol as the driving force behind the development of Alzheimer’s disease. Front Aging Neurosci. 2015;7:119. 26150787 PMC4473000 · DOI
  34. [39]Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature. 1995;375(6534):754–60. 7596406 · DOI · Paper page
  35. [40]Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease. Science. 1991;254(5028):97–9. 1925564 · DOI
  36. [41]Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, et al. Early-onset Alzheimer’s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature. 1991;353(6347):844–6. 1944558 · DOI · Paper page
  37. [42]Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991;349(6311):704–6. 1671712 · DOI · Paper page
  38. [43]Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(5):1977–81. 8446617 PMC46003 · DOI · Paper page
  39. [44]Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501–18. 31367008 PMC7055192 · DOI · Paper page
  40. [45]Rebeck GW. The role of APOE on lipid homeostasis and inflammation in normal brains. J Lipid Res. 2017;58(8):1493–9. 28258087 PMC5538293 · DOI · Paper page
  41. [47]Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS ONE. 2010;5(11):e13950. 21085570 PMC2981526 · DOI · Paper page
  42. [48]Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160(6):1061–71. 25728668 PMC4477963 · DOI · Paper page
  43. [49]Preman P, Arranz AM. A neuron-specific interaction between Alzheimer’s disease risk factors SORL1, APOE, and CLU. Cell Rep. 2023;42(9):113129. 37708025 · DOI
  44. [50]Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol. 2010;30(2):139–43. 19797709 PMC2812788 · DOI
  45. [51]Sakae N, Liu CC, Shinohara M, Frisch-Daiello J, Ma L, Yamazaki Y, et al. ABCA7 Deficiency accelerates amyloid-beta generation and Alzheimer’s neuronal Pathology. J Neurosci. 2016;36(13):3848–59. 27030769 PMC4812140 · DOI
  46. [52]Kawatani K, Holm ML, Starling SC, Martens YA, Zhao J, Lu W, et al. ABCA7 deficiency causes neuronal dysregulation by altering mitochondrial lipid metabolism. Mol Psychiatry. 2024;29(3):809–19. 38135757 PMC11153016 · DOI
  47. [53]Li L, Hua L, Fan H, He Y, Xu W, Zhang L, et al. Interplay of PKD3 with SREBP1 promotes cell growth via upregulating lipogenesis in prostate Cancer cells. J Cancer. 2019;10(25):6395–404. 31772672 PMC6856730 · DOI
  48. [54]Sun N, Shen C, Zhang L, Wu X, Yu Y, Yang X, et al. Hepatic kruppel-like factor 16 (KLF16) targets PPARalpha to improve steatohepatitis and insulin resistance. Gut. 2021;70(11):2183–95. 33257471 PMC8515101 · DOI
  49. [55]Balla T. Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev. 2013;93(3):1019–137. 23899561 PMC3962547 · DOI · Paper page
  50. [57]Maguire E, Menzies GE, Phillips T, Sasner M, Williams HM, Czubala MA, et al. PIP2 depletion and altered endocytosis caused by expression of Alzheimer’s disease-protective variant PLCgamma2 R522. EMBO J. 2021;40(17):e105603. 34254352 PMC8408593 · DOI · Paper page
  51. [58]Waddell GL, Drew EE, Rupp HP, Hansen SD. Mechanisms controlling membrane recruitment and activation of the autoinhibited SHIP1 inositol 5-phosphatase. J Biol Chem. 2023;299(8):105022. 37423304 PMC10448276 · DOI
  52. [59]Schneider N, Hauser J, Oliveira M, Cazaubon E, Mottaz SC, O’Neill BV et al. Sphingomyelin in Brain and Cognitive Development: Preliminary Data. eNeuro 2019;6(4). PMC6709232 31324675
  53. [60]MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest. 2007;117(1):153–64. 17200715 PMC1716206 · DOI · Paper page
  54. [61]Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40(1):1–16. 9869645 · DOI · Paper page
  55. [62]White PJ, McGarrah RW, Grimsrud PA, Tso SC, Yang WH, Haldeman JM, et al. The BCKDH kinase and Phosphatase Integrate BCAA and lipid metabolism via regulation of ATP-Citrate lyase. Cell Metab. 2018;27(6):1281–93. e7. 29779826 PMC5990471 · DOI · Paper page
  56. [64]Chen SZ, Ning LF, Xu X, Jiang WY, Xing C, Jia WP, et al. The miR-181d-regulated metalloproteinase Adamts1 enzymatically impairs adipogenesis via ECM remodeling. Cell Death Differ. 2016;23(11):1778–91. 27447109 PMC5071569 · DOI
  57. [65]Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology. 1993;43(8):1467–72. 8350998 · DOI · Paper page
  58. [67]Mahley RW, Apolipoprotein E. Cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622–30. 3283935 · DOI · Paper page
  59. [68]Wang N, Silver DL, Thiele C, Tall AR. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem. 2001;276(26):23742–7. 11309399 · DOI
  60. [69]Sun Y, Li X. Cholesterol efflux mechanism revealed by structural analysis of human ABCA1 conformational states. Nat Cardiovasc Res. 2022;1(3):238–45. 37181814 PMC10181854 · DOI
  61. [70]Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet. 2011;43(5):429–35. 21460840 PMC3084173 · DOI · Paper page
  62. [71]Wang N, Lan D, Gerbod-Giannone M, Linsel-Nitschke P, Jehle AW, Chen W, et al. ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux. J Biol Chem. 2003;278(44):42906–12. 12917409 · DOI
  63. [72]von Maydell D, Wright S, Bonner JM, Staab C, Spitaleri A, Liu L et al. Single-cell atlas of ABCA7 loss-of-function reveals impaired neuronal respiration via choline-dependent lipid imbalances. bioRxiv. 2024.
  64. [73]Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168–77. 17220890 PMC2657343 · DOI · Paper page
  65. [74]Jensen AMG, Raska J, Fojtik P, Monti G, Lunding M, Bartova S, et al. The SORL1 p.Y1816C variant causes impaired endosomal dimerization and autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci U S A. 2024;121(37):e2408262121. 39226352 PMC11406263 · DOI
  66. [75]Conlon DM. Role of sortilin in lipid metabolism. Curr Opin Lipidol. 2019;30(3):198–204. 30946050 · DOI
  67. [76]Asaro A, Sinha R, Bakun M, Kalnytska O, Carlo-Spiewok AS, Rubel T et al. ApoE4 disrupts interaction of sortilin with fatty acid-binding protein 7 essential to promote lipid signaling. J Cell Sci 2021;134(20). PMC8572006 34557909
  68. [77]Ko YA, Billheimer JT, Lyssenko NN, Kueider-Paisley A, Wolk DA, Arnold SE, et al. ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer’s disease. Alzheimers Res Ther. 2022;14(1):194. 36572909 PMC9791777 · DOI
  69. [78]Laslo A, Laslo L, Arbanasi EM, Ujlaki-Nagi AA, Chinezu L, Ivanescu AD, et al. Pathways to Alzheimer’s Disease: the intersecting roles of Clusterin and apolipoprotein E in amyloid-beta regulation and neuronal health. Pathophysiology. 2024;31(4):545–58. 39449522 PMC11503414 · DOI
  70. [79]Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117–27. 23150934 PMC3631573 · DOI · Paper page
  71. [80]Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368(2):107–16. 23150908 PMC3677583 · DOI · Paper page
  72. [82]Gouna G, Klose C, Bosch-Queralt M, Liu L, Gokce O, Schifferer M et al. TREM2-dependent lipid droplet biogenesis in phagocytes is required for remyelination. J Exp Med 2021;218(10). PMC8404472 34424266
  73. [84]Wei W, Zhang L, Xin W, Pan Y, Tatenhorst L, Hao Z, et al. TREM2 regulates microglial lipid droplet formation and represses post-ischemic brain injury. Biomed Pharmacother. 2024;170:115962. 38042110 · DOI · Paper page
  74. [87]Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45(12):1452–8. 24162737 PMC3896259 · DOI · Paper page
  75. [88]Samuels JD, Moore KA, Ennerfelt HE, Johnson AM, Walsh AE, Price RJ, et al. The Alzheimer’s disease risk factor INPP5D restricts neuroprotective microglial responses in amyloid beta-mediated pathology. Alzheimers Dement. 2023;19(11):4908–21. 37061460 PMC10576836 · DOI · Paper page
  76. [89]Wit M, Belykh A, Sumara G. Protein kinase D (PKD) on the crossroad of lipid absorption, synthesis and utilization. Biochim Biophys Acta Mol Cell Res. 2024;1871(2):119653. 38104800 · DOI
  77. [90]Tellier E, Canault M, Rebsomen L, Bonardo B, Juhan-Vague I, Nalbone G, et al. The shedding activity of ADAM17 is sequestered in lipid rafts. Exp Cell Res. 2006;312(20):3969–80. 17010968 · DOI
  78. [91]Kothari V, Tang J, He Y, Kramer F, Kanter JE, Bornfeldt KE. ADAM17 boosts cholesterol efflux and downstream effects of High-Density Lipoprotein on Inflammatory pathways in Macrophages. Arterioscler Thromb Vasc Biol. 2021;41(6):1854–73. 33882688 PMC8159900 · DOI
  79. [92]Wilsie LC, Chanchani S, Navaratna D, Orlando RA. Cell surface heparan sulfate proteoglycans contribute to intracellular lipid accumulation in adipocytes. Lipids Health Dis. 2005;4:2. 15636641 PMC545935 · DOI
  80. [93]Wei Y, Xiong ZJ, Li J, Zou C, Cairo CW, Klassen JS, et al. Crystal structures of human lysosomal EPDR1 reveal homology with the superfamily of bacterial lipoprotein transporters. Commun Biol. 2019;2:52. 30729188 PMC6363788 · DOI
  81. [94]Deshmukh AS, Peijs L, Beaudry JL, Jespersen NZ, Nielsen CH, Ma T, et al. Proteomics-based comparative mapping of the secretomes of Human Brown and White adipocytes reveals EPDR1 as a Novel Batokine. Cell Metab. 2019;30(5):963–75. e7. 31668873 · DOI
  82. [96]Hernandez-Diaz S, Soukup SF. The role of lipids in autophagy and its implication in neurodegeneration. Cell Stress. 2020;4(7):167–86. 32656499 PMC7328674 · DOI
  83. [97]Ford MG, Pearse BM, Higgins MK, Vallis Y, Owen DJ, Gibson A, et al. Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science. 2001;291(5506):1051–5. 11161218 · DOI
  84. [98]Paveskovic M, De-Paula RB, Ojelade SA, Tantry EK, Kochukov MY, Bao S, et al. Alzheimer’s disease risk gene CD2AP is a dose-sensitive determinant of synaptic structure and plasticity. Hum Mol Genet. 2024;33(20):1815–32. 39146503 PMC11458016 · DOI
  85. [99]Pant S, Sharma M, Patel K, Caplan S, Carr CM, Grant BD. AMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling. Nat Cell Biol. 2009;11(12):1399–410. 19915558 PMC2788952 · DOI · Paper page
  86. [100]Jones L, Harold D, Williams J. Genetic evidence for the involvement of lipid metabolism in Alzheimer’s disease. Biochim Biophys Acta. 2010;1801(8):754–61. 20420935 · DOI
  87. [101]Jang MK, Lee S, Jung MH. RNA-Seq analysis reveals a negative role of KLF16 in Adipogenesis. PLoS ONE. 2016;11(9):e0162238. 27611969 PMC5017575 · DOI
  88. [102]Kim M, Wende H, Walcher J, Kuhnemund J, Cheret C, Kempa S, et al. Maf links Neuregulin1 signaling to cholesterol synthesis in myelinating Schwann cells. Genes Dev. 2018;32(9–10):645–57. 29748249 PMC6004071 · DOI
  89. [103]Han X, Gross RW. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J Lipid Res. 2003;44(6):1071–9. 12671038 · DOI · Paper page
  90. [104]Yang K, Han X, Lipidomics. Techniques, applications, and outcomes related to Biomedical sciences. Trends Biochem Sci. 2016;41(11):954–69. PMC5085849 27663237
  91. [105]Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497–509. 13428781 · DOI · Paper page
  92. [107]Breil C, Abert Vian M, Zemb T, Kunz W, Chemat F. Bligh and Dyer and Folch methods for solid-liquid-liquid extraction of lipids from microorganisms. Comprehension of Solvatation mechanisms and towards substitution with alternative solvents. Int J Mol Sci 2017;18(4). PMC5412294 28346372
  93. [108]Matyash V, Liebisch G, Kurzchalia TV, Shevchenko A, Schwudke D. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res. 2008;49(5):1137–46. 18281723 PMC2311442 · DOI
  94. [109]Lofgren L, Stahlman M, Forsberg GB, Saarinen S, Nilsson R, Hansson GI. The BUME method: a novel automated chloroform-free 96-well total lipid extraction method for blood plasma. J Lipid Res. 2012;53(8):1690–700. 22645248 PMC3540853 · DOI
  95. [110]Han X, Gross RW. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev. 2005;24(3):367–412. 15389848 · DOI
  96. [111]Martin AJ, Synge RL. A new form of chromatogram employing two liquid phases: a theory of chromatography. 2. Application to the micro-determination of the higher monoamino-acids in proteins. Biochem J. 1941;35(12):1358–68. 16747422 PMC1265645 · DOI
  97. [112]Horvath CG, Preiss BA, Lipsky SR. Fast liquid chromatography: an investigation of operating parameters and the separation of nucleotides on pellicular ion exchangers. Anal Chem. 1967;39(12):1422–8. 6073805 · DOI
  98. [113]Alpert AJ. Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids and other polar compounds. J Chromatogr. 1990;499:177–96. 2324207 · DOI
  99. [114]Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science. 1989;246(4926):64–71. 2675315 · DOI · Paper page
  100. [115]Robb DB, Covey TR, Bruins AP. Atmospheric pressure photoionization: an ionization method for liquid chromatography-mass spectrometry. Anal Chem. 2000;72(15):3653–9. 10952556 · DOI
  101. [116]Hillenkamp F, Karas M, Beavis RC, Chait BT. Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. Anal Chem. 1991;63(24):A1193–203. 1789447 · DOI · Paper page
  102. [117]Takats Z, Wiseman JM, Gologan B, Cooks RG. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. Science. 2004;306(5695):471–3. 15486296 · DOI
  103. [118]Li M, Yang L, Bai Y, Liu H. Analytical methods in lipidomics and their applications. Anal Chem. 2014;86(1):161–75. 24215393 · DOI
  104. [119]Samfors S, Fletcher JS. Lipid diversity in cells and tissue using imaging SIMS. Annu Rev Anal Chem (Palo Alto Calif). 2020;13(1):249–71. 32212820 · DOI
  105. [120]Han X, Gross RW. Quantitative analysis and molecular species fingerprinting of triacylglyceride molecular species directly from lipid extracts of biological samples by electrospray ionization tandem mass spectrometry. Anal Biochem. 2001;295(1):88–100. 11476549 · DOI · Paper page
  106. [121]Wang M, Wang C, Han RH, Han X. Novel advances in shotgun lipidomics for biology and medicine. Prog Lipid Res. 2016;61:83–108. 26703190 PMC4733395 · DOI
  107. [122]Han X, Yang K, Yang J, Fikes KN, Cheng H, Gross RW. Factors influencing the electrospray intrasource separation and selective ionization of glycerophospholipids. J Am Soc Mass Spectrom. 2006;17(2):264–74. 16413201 · DOI
  108. [124]Fantini J, Barrantes FJ. Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim Biophys Acta. 2009;1788(11):2345–61. 19733149 · DOI
  109. [125]Codini M, Garcia-Gil M, Albi E. Cholesterol and sphingolipid enriched lipid rafts as therapeutic targets in Cancer. Int J Mol Sci 2021;22(2). PMC7828315 33450869
  110. [126]Jesko H, Stepien A, Lukiw WJ, Strosznajder RP. The Cross-talk between sphingolipids and insulin-like growth factor signaling: significance for aging and neurodegeneration. Mol Neurobiol. 2019;56(5):3501–21. 30140974 PMC6476865 · DOI
  111. [127]Czubowicz K, Jesko H, Wencel P, Lukiw WJ, Strosznajder RP. The role of Ceramide and Sphingosine-1-Phosphate in Alzheimer’s Disease and Other Neurodegenerative disorders. Mol Neurobiol. 2019;56(8):5436–55. 30612333 PMC6614129 · DOI
  112. [128]Crivelli SM, Giovagnoni C, Visseren L, Scheithauer AL, de Wit N, den Hoedt S, et al. Sphingolipids in Alzheimer’s disease, how can we target them? Adv Drug Deliv Rev. 2020;159:214–31. 31911096 · DOI
  113. [129]Couttas TA, Kain N, Suchowerska AK, Quek LE, Turner N, Fath T, et al. Loss of ceramide synthase 2 activity, necessary for myelin biosynthesis, precedes tau pathology in the cortical pathogenesis of Alzheimer’s disease. Neurobiol Aging. 2016;43:89–100. 27255818 · DOI
  114. [130]Olsen ASB, Faergeman NJ. Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol 2017;7(5). PMC5451547 28566300
  115. [132]He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiol Aging. 2010;31(3):398–408. 18547682 PMC2829762 · DOI · Paper page
  116. [133]Mielke MM, Haughey NJ, Bandaru VV, Schech S, Carrick R, Carlson MC, et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement. 2010;6(5):378–85. 20813340 PMC2933928 · DOI · Paper page
  117. [135]Huang HX, Inglese P, Tang J, Yagoubi R, Correia GDS, Horneffer-van der Sluis VM, et al. Mass spectrometry imaging highlights dynamic patterns of lipid co-expression with Abeta plaques in mouse and human brains. J Neurochem. 2024;168(7):1193–214. 38372586 · DOI
  118. [136]Akyol S, Ugur Z, Yilmaz A, Ustun I, Gorti SKK, Oh K et al. Lipid Profiling of Alzheimer’s Disease Brain Highlights Enrichment in Glycerol(phospho)lipid, and Sphingolipid Metabolism. Cells 2021;10(10). PMC8534054 34685570
  119. [137]Bandaru VV, Troncoso J, Wheeler D, Pletnikova O, Wang J, Conant K, et al. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer’s but not normal brain. Neurobiol Aging. 2009;30(4):591–9. 17888544 PMC2758772 · DOI
  120. [138]Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci U S A. 2004;101(7):2070–5. 14970312 PMC357053 · DOI
  121. [139]Katsel P, Li C, Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease? Neurochem Res. 2007;32(4–5):845–56. 17342407 · DOI
  122. [140]Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ. Brain membrane phospholipid alterations in Alzheimer’s disease. Neurochem Res. 2001;26(7):771–82. 11565608 · DOI
  123. [141]Baloni P, Arnold M, Buitrago L, Nho K, Moreno H, Huynh K, et al. Multi-omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer’s disease. Commun Biol. 2022;5(1):1074. 36209301 PMC9547905 · DOI
  124. [142]Yuyama K, Mitsutake S, Igarashi Y. Pathological roles of ceramide and its metabolites in metabolic syndrome and Alzheimer’s disease. Biochim Biophys Acta. 2014;1841(5):793–8. 23948264 · DOI
  125. [143]Huang Y, Tanimukai H, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX. Elevation of the level and activity of acid ceramidase in Alzheimer’s disease brain. Eur J Neurosci. 2004;20(12):3489–97. 15610181 · DOI
  126. [144]Jesko H, Okada T, Strosznajder RP, Nakamura S. Sphingosine kinases modulate the secretion of amyloid beta precursor protein from SH-SY5Y neuroblastoma cells: the role of alpha-synuclein. Folia Neuropathol. 2014;52(1):70–8. 24729344 · DOI
  127. [145]Couttas TA, Kain N, Daniels B, Lim XY, Shepherd C, Kril J, et al. Loss of the neuroprotective factor sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis. Acta Neuropathol Commun. 2014;2:9. 24456642 PMC3906863 · DOI · Paper page
  128. [146]Presa N, Gomez-Larrauri A, Dominguez-Herrera A, Trueba M, Gomez-Munoz A. Novel signaling aspects of ceramide 1-phosphate. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(4):158630. 31958571 · DOI
  129. [147]Uranbileg B, Isago H, Sakai E, Kubota M, Saito Y, Kurano M. Alzheimer’s disease manifests abnormal sphingolipid metabolism. Front Aging Neurosci. 2024;16:1368839. 38774265 PMC11106446 · DOI
  130. [148]Svennerholm L, Gottfries CG. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem. 1994;62(3):1039–47. 8113790 · DOI
  131. [149]Hejazi L, Wong JW, Cheng D, Proschogo N, Ebrahimi D, Garner B, et al. Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer’s disease brains. Biochem J. 2011;438(1):165–75. 21639855 · DOI
  132. [150]Yu RK, Tsai YT, Ariga T, Yanagisawa M. Structures, biosynthesis, and functions of gangliosides–an overview. J Oleo Sci. 2011;60(10):537–44. 21937853 PMC3684167 · DOI
  133. [151]Bernardo A, Harrison FE, McCord M, Zhao J, Bruchey A, Davies SS, et al. Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice. Neurobiol Aging. 2009;30(11):1777–91. 18258340 · DOI · Paper page
  134. [152]Taki T. An approach to glycobiology from glycolipidomics: ganglioside molecular scanning in the brains of patients with Alzheimer’s disease by TLC-blot/matrix assisted laser desorption/ionization-time of flight MS. Biol Pharm Bull. 2012;35(10):1642–7. 23037154 · DOI
  135. [153]Kracun I, Kalanj S, Talan-Hranilovic J, Cosovic C. Cortical distribution of gangliosides in Alzheimer’s disease. Neurochem Int. 1992;20(3):433–8. 1304338 · DOI
  136. [154]Eckhardt M. The role and metabolism of sulfatide in the nervous system. Mol Neurobiol. 2008;37(2–3):93–103. 18465098 · DOI · Paper page
  137. [155]Stoffyn PJ. The structure and chemistry of sulfatides. J Am Oil Chem Soc. 1966;43(2):69–74. 5902881 · DOI
  138. [156]Kyogashima M, Tamiya-Koizumi K, Ehara T, Li G, Hu R, Hara A, et al. Rapid demonstration of diversity of sulfatide molecular species from biological materials by MALDI-TOF MS. Glycobiology. 2006;16(8):719–28. 16670104 · DOI
  139. [157]Takahashi T, Suzuki T. Role of sulfatide in normal and pathological cells and tissues. J Lipid Res. 2012;53(8):1437–50. 22619219 PMC3540844 · DOI
  140. [158]Svennerholm L, Stallberg-Stenhagen S. Changes in the fatty acid composition of cerebrosides and sulfatides of human nervous tissue with age. J Lipid Res. 1968;9(2):215–25. 5640502 · DOI
  141. [159]Torello LB, Yates AJ, Hart R, Leon KS. A comparative-evolutionary study of lipids in the aging brain of mice. Neurobiol Aging. 1986;7(5):337–46. 3785533 · DOI
  142. [160]Han X. Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer’s disease: a tale of shotgun lipidomics. J Neurochem. 2007;103(1):171–9. 17986152 PMC2147059 · DOI · Paper page
  143. [161]Cheng H, Wang M, Li JL, Cairns NJ, Han X. Specific changes of sulfatide levels in individuals with pre-clinical Alzheimer’s disease: an early event in disease pathogenesis. J Neurochem. 2013;127(6):733–8. 23865640 PMC3844035 · DOI
  144. [162]Gonzalez de San Roman E, Manuel I, Giralt MT, Ferrer I, Rodriguez-Puertas R. Imaging mass spectrometry (IMS) of cortical lipids from preclinical to severe stages of Alzheimer’s disease. Biochim Biophys Acta Biomembr. 2017;1859(9 Pt B):1604–14. 28527668 · DOI
  145. [163]Zimmer VC, Lauer AA, Haupenthal V, Stahlmann CP, Mett J, Grosgen S, et al. A bidirectional link between sulfatide and Alzheimer’s disease. Cell Chem Biol. 2024;31(2):265–83. e7. 37972592 · DOI
  146. [164]Yuki D, Sugiura Y, Zaima N, Akatsu H, Hashizume Y, Yamamoto T, et al. Hydroxylated and non-hydroxylated sulfatide are distinctly distributed in the human cerebral cortex. Neuroscience. 2011;193:44–53. 21802498 · DOI
  147. [167]Xu Z, He S, Begum MM, Han X. Myelin lipid alterations in neurodegenerative diseases: Landscape and pathogenic implications. Antioxid Redox Signal. 2024;41(16–18):1073–99. 39575748 PMC11971557 · DOI
  148. [168]Marbois BN, Faull KF, Fluharty AL, Raval-Fernandes S, Rome LH. Analysis of sulfatide from rat cerebellum and multiple sclerosis white matter by negative ion electrospray mass spectrometry. Biochim Biophys Acta. 2000;1484(1):59–70. 10685031 · DOI
  149. [169]Pintado-Sierra M, Garcia-Alvarez I, Bribian A, Medina-Rodriguez EM, Lebron-Aguilar R, Garrido L, et al. A comprehensive profiling of sulfatides in myelin from mouse brain using liquid chromatography coupled to high-resolution accurate tandem mass spectrometry. Anal Chim Acta. 2017;951:89–98. 27998489 · DOI
  150. [170]Blomqvist M, Boren J, Zetterberg H, Blennow K, Mansson JE, Stahlman M. High-throughput analysis of sulfatides in cerebrospinal fluid using automated extraction and UPLC-MS/MS. J Lipid Res. 2017;58(7):1482–9. 28550076 PMC5496026 · DOI
  151. [171]Cedazo-Minguez A, Cowburn RF. Apolipoprotein E: a major piece in the Alzheimer’s disease puzzle. J Cell Mol Med. 2001;5(3):254–66. 12067484 PMC6514775 · DOI
  152. [172]Han X, Cheng H, Fryer JD, Fagan AM, Holtzman DM. Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content. J Biol Chem. 2003;278(10):8043–51. 12501252 · DOI · Paper page
  153. [173]Cheng H, Zhou Y, Holtzman DM, Han X. Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer’s disease. Neurobiol Aging. 2010;31(7):1188–96. 18762354 PMC2873070 · DOI · Paper page
  154. [174]Han X. The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer’s disease. Mol Neurobiol. 2010;41(2–3):97–106. 20052565 PMC2877150 · DOI
  155. [175]Qiu S, Palavicini JP, Wang J, Gonzalez NS, He S, Dustin E, et al. Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer’s disease-like neuroinflammation and cognitive impairment. Mol Neurodegener. 2021;16(1):64. 34526055 PMC8442347 · DOI
  156. [176]Coetzee T, Fujita N, Dupree J, Shi R, Blight A, Suzuki K, et al. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell. 1996;86(2):209–19. 8706126 · DOI
  157. [177]Palavicini JP, Wang C, Chen L, Ahmar S, Higuera JD, Dupree JL, et al. Novel molecular insights into the critical role of sulfatide in myelin maintenance/function. J Neurochem. 2016;139(1):40–54. 27417284 PMC5037006 · DOI
  158. [178]Marcus J, Honigbaum S, Shroff S, Honke K, Rosenbluth J, Dupree JL. Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia. 2006;53(4):372–81. 16288467 · DOI
  159. [179]Potter KA, Kern MJ, Fullbright G, Bielawski J, Scherer SS, Yum SW, et al. Central nervous system dysfunction in a mouse model of FA2H deficiency. Glia. 2011;59(7):1009–21. 21491498 PMC3094470 · DOI
  160. [180]Dustin E, McQuiston AR, Honke K, Palavicini JP, Han X, Dupree JL. Adult-onset depletion of sulfatide leads to axonal degeneration with relative myelin sparing. Glia. 2023;71(9):2285–303. 37283058 PMC11007682 · DOI
  161. [181]Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton RA, Lu A, et al. Cerebral ventricular changes associated with transitions between normal cognitive function, mild cognitive impairment, and dementia. Alzheimer Dis Assoc Disord. 2007;21(1):14–24. 17334268 PMC2879163 · DOI
  162. [182]Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, et al. Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database. Brain. 2008;131(Pt 9):2443–54. 18669512 PMC2724905 · DOI · Paper page
  163. [183]Palavicini JP, Ding L, Pan M, Qiu S, Wang H, Shen Q et al. Sulfatide Deficiency, an Early Alzheimer’s Lipidomic Signature, Causes Brain Ventricular Enlargement in the Absence of Classical Neuropathological Hallmarks. Int J Mol Sci 2022;24(1). PMC9820719 36613677
  164. [184]Morris JK, Honea RA, Vidoni ED, Swerdlow RH, Burns JM. Is Alzheimer’s disease a systemic disease? Biochim Biophys Acta. 2014;1842(9):1340–9. 24747741 PMC4126236 · DOI · Paper page
  165. [185]He S, Qiu S, Pan M, Palavicini JP, Wang H, Li X, et al. Central nervous system sulfatide deficiency as a causal factor for bladder disorder in Alzheimer’s disease. Clin Transl Med. 2023;13(7):e1332. 37478300 PMC10361545 · DOI
  166. [186]Brunnstrom HR, Englund EM. Cause of death in patients with dementia disorders. Eur J Neurol. 2009;16(4):488–92. 19170740 · DOI · Paper page
  167. [188]Tsai CL, Pan CY, Chen FC, Huang TH, Tsai MC, Chuang CY. Differences in neurocognitive performance and metabolic and inflammatory indices in male adults with obesity as a function of regular exercise. Exp Physiol. 2019;104(11):1650–60. 31609518 · DOI
  168. [190]Palavicini JP, Chen J, Wang C, Wang J, Qin C, Baeuerle E, et al. Early disruption of nerve mitochondrial and myelin lipid homeostasis in obesity-induced diabetes. JCI Insight. 2020;5:21. PMC7710310 33148881 · DOI
  169. [191]Roh E, Kim MS. Brain regulation of Energy Metabolism. Endocrinol Metab (Seoul). 2016;31(4):519–24. 28029023 PMC5195827 · DOI
  170. [192]Furlan A, Petrus P. Brain-body communication in metabolic control. Trends Endocrinol Metab. 2023;34(12):813–22. 37716877 · DOI
  171. [193]Qiu S, He S, Wang J, Wang H, Bhattacharjee A, Li X et al. Adult-onset CNS Sulfatide Deficiency causes sex-dependent metabolic disruption in aging. Int J Mol Sci 2023;24(13). PMC10341976 37445661
  172. [195]Zakany F, Kovacs T, Panyi G, Varga Z. Direct and indirect cholesterol effects on membrane proteins with special focus on potassium channels. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(8):158706. 32247032 · DOI
  173. [196]Wang C, Yue H, Hu Z, Shen Y, Ma J, Li J, et al. Microglia mediate forgetting via complement-dependent synaptic elimination. Science. 2020;367(6478):688–94. 32029629 · DOI · Paper page
  174. [198]Saher G, Brugger B, Lappe-Siefke C, Mobius W, Tozawa R, Wehr MC, et al. High cholesterol level is essential for myelin membrane growth. Nat Neurosci. 2005;8(4):468–75. 15793579 · DOI · Paper page
  175. [199]Hughes TM, Rosano C, Evans RW, Kuller LH. Brain cholesterol metabolism, oxysterols, and dementia. J Alzheimers Dis. 2013;33(4):891–911. 23076077 PMC4354887 · DOI
  176. [201]Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(3):a006312. 22393530 PMC3282491 · DOI · Paper page
  177. [202]Liu LC, Liang JY, Liu YH, Liu B, Dong XH, Cai WH, et al. The intersection of cerebral cholesterol metabolism and Alzheimer’s disease: mechanisms and therapeutic prospects. Heliyon. 2024;10(9):e30523. 38726205 PMC11079309 · DOI
  178. [203]Di Paolo G, Kim TW. Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat Rev Neurosci. 2011;12(5):284–96. 21448224 PMC3321383 · DOI · Paper page
  179. [204]Abuznait AH, Kaddoumi A. Role of ABC transporters in the pathogenesis of Alzheimer’s disease. ACS Chem Neurosci. 2012;3(11):820–31. 23181169 PMC3504479 · DOI
  180. [206]Rizwan M, Aslam N, Ashfaq UA, Hayat M, Hussain SM. SNP of HMGCR and apo E genes and their impact in response to statin therapy in hypercholesterolemic and hypertriglyceridemic patients in Pakistan. Pak J Pharm Sci. 2021;34(4Supplementary):1577–83. 34799335
  181. [207]Azizidoost S, Babaahmadi-Rezaei H, Nazeri Z, Cheraghzadeh M, Kheirollah A. Amyloid beta increases ABCA1 and HMGCR protein expression, and cholesterol synthesis and accumulation in mice neurons and astrocytes. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(1):159069. 34744007 · DOI
  182. [208]Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat Neurosci. 2003;6(4):345–51. 12658281 · DOI
  183. [209]Ahmed H, Wang Y, Griffiths WJ, Levey AI, Pikuleva I, Liang SH, et al. Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development. Brain. 2024;147(5):1622–35. 38301270 PMC11068113 · DOI
  184. [210]Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A. 1992;89(5):1671–5. 1311847 PMC48514 · DOI
  185. [211]Farooqui AA, Horrocks LA, Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem Phys Lipids. 2000;106(1):1–29. 10878232 · DOI · Paper page
  186. [212]Farooqui AA, Rapoport SI, Horrocks LA. Membrane phospholipid alterations in Alzheimer’s disease: deficiency of ethanolamine plasmalogens. Neurochem Res. 1997;22(4):523–7. 9130265 · DOI
  187. [213]Stephenson D, Rash K, Smalstig B, Roberts E, Johnstone E, Sharp J, et al. Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration. Glia. 1999;27(2):110–28. 10417811 · DOI
  188. [214]Kuczynski B, Reo NV. Evidence that plasmalogen is protective against oxidative stress in the rat brain. Neurochem Res. 2006;31(5):639–56. 16770735 · DOI
  189. [215]Guan Z, Wang Y, Cairns NJ, Lantos PL, Dallner G, Sindelar PJ. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol. 1999;58(7):740–7. 10411344 · DOI
  190. [216]Han X, Holtzman DM, McKeel DW. Jr. Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem. 2001;77(4):1168–80. 11359882 · DOI
  191. [218]Hossain MS, Mawatari S, Honsho M, Okauchi T, Fujino T. KIT-13, a novel plasmalogen derivative, attenuates neuroinflammation and amplifies cognition. Front Cell Dev Biol. 2024;12:1443536. 39286482 PMC11402709 · DOI
  192. [219]Zhai Y, Morihara R, Feng T, Hu X, Fukui Y, Bian Z, et al. Protective effect of scallop-derived plasmalogen against vascular dysfunction, via the pSTAT3/PIM1/NFATc1 axis, in a novel mouse model of Alzheimer’s disease with cerebral hypoperfusion. Brain Res. 2024;1828:148790. 38272156 · DOI
  193. [220]Smith T, Knudsen KJ, Ritchie SA. A novel inducible animal model for studying chronic plasmalogen deficiency associated with Alzheimer’s disease. Brain Res. 2024;1843:149132. 39053687 · DOI
  194. [221]Hamu-Tanoue A, Takagi K, Taketomi Y, Miki Y, Nishito Y, Kano K, et al. Group III secreted phospholipase A(2) -driven lysophospholipid pathway protects against allergic asthma. FASEB J. 2024;38(2):e23428. 38236184 · DOI
  195. [222]Hu C, Wang M, Han X. Shotgun lipidomics in substantiating lipid peroxidation in redox biology: methods and applications. Redox Biol. 2017;12:946–55. 28494428 PMC5423350 · DOI
  196. [223]Frisardi V, Panza F, Seripa D, Farooqui T, Farooqui AA. Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer’s disease pathology. Prog Lipid Res. 2011;50(4):313–30. 21703303 · DOI
  197. [224]Kurano M, Saito Y, Uranbileg B, Saigusa D, Kano K, Aoki J, et al. Modulations of bioactive lipids and their receptors in postmortem Alzheimer’s disease brains. Front Aging Neurosci. 2022;14:1066578. 36570536 PMC9780287 · DOI
  198. [225]Ryan SD, Whitehead SN, Swayne LA, Moffat TC, Hou W, Ethier M, et al. Amyloid-beta42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. Proc Natl Acad Sci U S A. 2009;106(49):20936–41. 19926863 PMC2791600 · DOI
  199. [226]Sabogal-Guaqueta AM, Arias-Londono JD, Gutierrez-Vargas J, Sepulveda-Falla D, Glatzel M, Villegas-Lanau A, et al. Common disbalance in the brain parenchyma of dementias: phospholipid profile analysis between CADASIL and sporadic Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis. 2020;1866(8):165797. 32302650 · DOI
  200. [227]Kalecky K, German DC, Montillo AA, Bottiglieri T. Targeted metabolomic analysis in Alzheimer’s Disease plasma and brain tissue in non-hispanic whites. J Alzheimers Dis. 2022;86(4):1875–95. 35253754 PMC9108583 · DOI

200 of 366 shown

Cited by

Sorted by citations

Authors
He, S., Xu, Z., & Han, X.
Affiliations
The University of Texas at San Antonio Health Science Center (US)
Corresponding author
Han, Xianlin
ORCID
Venue
Molecular Neurodegeneration
Publisher
Springer Science and Business Media LLC
Published
2025-01-27
Volume
20
Issue
1
Pages
11-11
ISSN
1750-1326 (ISSN-L)
DOI
10.1186/s13024-025-00803-6
PMC
PMC11773937
OpenAlex
W4406861008
Cited by
62
References
43
Citations by year
2026: 43 · 2025: 19
FWCI
8.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute on Aging (R01 AG085545, R01 AG061872, RF1 AG061729, T32 AG021890, P30 AG066546, P30 AG013319, P30 AG044271)
  • University of Texas Health Science Center at San Antonio (University of Texas Health Science Center at San Antonio)
  • Methodist Hospital Foundation (Methodist Hospital Foundation)
  • Cure Alzheimer's Fund (Cure Alzheimer's Fund)
  • William and Ella Owens Medical Research Foundation (William and Ella Owens Medical Research Foundation)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords
Alzheimer's disease, lipidomics, lipid dysregulation, brain lipids, amyloid-beta, tau protein, neuroinflammation, neurodegeneration
MeSH terms
Lipidomics, Alzheimer Disease, Animals, Brain, Humans, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review